February 2026 FDA Recall Eptifibatide by Slate Run Pharmaceuticals
D-0343-2026 - Labeling

This Class III drug recall was voluntarily initiated by Slate Run Pharmaceuticals on February 12, 2026 for the product Eptifibatide. The FDA reported the reason for recall as labeling. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0343-2026

Reason for Recall
Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.
Initiated
02-12-2026
Reported
03-04-2026
Quantity
N/A

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Slate Run Pharmaceuticals
Nationwide within the USA.
Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL Single-dose Vial, For Intravenous Use Only, Rx Only, Manufactured by: Hainan Poly Pharm. Co., Ltd., Guilinyang Economic Development Area, Haikou, Hainan Province, China 571127; Distributed by: Slate Run Pharmaceuticals, LLC, Columbus, Ohio 43215. NDC Slate Run Carton Label: 70436-027-80; NDC ProRx Carton Label: 70436-163-80

Batch or Lot Expiration Information

Lot# All lots within expiry